Small Molecule CDMO Market Projected to Reach USD 135.75 Billion by 2035

The global market for small molecule contract development and manufacturing organizations (CDMOs) is forecast to expand significantly, reaching USD 135.75 billion by 2035. The market was estimated at USD 75.83 billion in 2025 and is expected to grow at a compound annual growth rate (CAGR) of 6% from 2026 to 2035.

Several factors are contributing to this growth, including the rising demand for outsourced pharmaceutical development and manufacturing services, increased drug discovery activities, and the growing complexity of small molecule therapies. Pharmaceutical and biotechnology firms are increasingly engaging CDMOs to leverage their specialized expertise, advanced manufacturing facilities, regulatory competence, and scale-up capabilities.

The small molecule CDMO market encompasses organizations that provide development and manufacturing services for active pharmaceutical ingredients (APIs), intermediates, and finished dosage forms for small molecule drugs. These entities support pharmaceutical and biotech organizations throughout the drug lifecycle, from process development and formulation to analytical testing, clinical trial production, and commercial manufacturing.

Key drivers for this expansion include the pharmaceutical industry's trend toward greater outsourcing to reduce costs and enhance agility, a robust pipeline of small molecule drugs that continue to dominate the market, and increased R&D investments by biopharmaceutical companies. The growing number of emerging biotech companies and the demand for CDMOs specializing in complex APIs are also contributing to market growth.